A new treatment approach for lethal drug-resistant bacterial skin infections
Active Grant Awarded
- Award ID
- R41AI197653
- Recipient
-
Mirofend LLC UEI J4RDBKNNAZH9
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $303,933
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 21% complete
- Place of performance
- Dallas, TX 75230, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded Mirofend LLC a grant totaling $303,933 on September 9, 2026, under Assistance Listing 93.855, Allergy and Infectious Diseases Research. The program supports biomedical research on infectious, immunologic, and allergic diseases. Under this Phase I application, Mirofend will solidify the efficacy of a patent-pending approach for managing Staphylococcus aureus infections, using in vitro assays and several mouse models of infection. The work is intended to advance commercialization of a new treatment for lethal bacterial skin infections, including drug-resistant strains. The full $303,933 is obligated. The period of performance runs from September 9, 2026, through August 31, 2027. Place of performance is Dallas, Texas 75230, USA.
Description
- Abstract
- Staphylococcus aureus soft tissue and skin infections affect seven-to-ten percent of hospitalized patients and skin infections are the third most common reason for presentation to the emergency room. Most infections of the skin are caused by S. Aureus, with men having higher rates of infection with S. Aureus compared to women. Adding to the burden of disease posed by these pathogens has been the development of antibiotic-resistant strains of bacteria such as methicillin-resistant S. Aureus (MRSA). Furthermore, S. Aureus exacerbates the inflammatory skin condition, atopic dermatitis (ad), that affects thirteen percent of adults and twenty percent of children in the united states. The pathogenesis of ad is incompletely understood, and there is an increasing appreciation for the contributions of the microbiome in ad pathogenesis. During ad flares, S. Aureus expands and exacerbates inflammatory responses and skin damage. Given the societal burden of S. Aureus and the expanding antibiotic resistance, new treatment approaches are needed. We have now discovered a patent- pending approach for the management of S. Aureus infections. In this phase I application we will solidify the efficacy of this treatment through the use of in vitro assays and several mouse models of infection. The work proposed will fuel the commercialization of a new approach for the treatment of lethal bacterial infections in the skin.
Quick answers
Who received award R41AI197653?
R41AI197653 was awarded to Mirofend LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 9, 2026.
How much is award R41AI197653 worth?
$303,933 has been obligated on R41AI197653.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award